Walbrook PR, one of the UK’s leading providers of Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as PR & IR advisor to Abingdon Health plc (“Abingdon”), a leading international
developer and manufacturer of high quality and effective rapid tests. The team at Walbrook will manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private
Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial
concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to
support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster
access to results allows for rapid decision making, targeted intervention and can support better outcomes.
This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient,
standalone lateral-flow reader.
Paul McManus, Founder and Managing Director of Walbrook PR, commented: “We are delighted to have been chosen by Abingdon to provide Financial Comms and Investor Relations support. The Company is a world leading developer and manufacturer of high-quality rapid tests, with significant addressable markets across various industries. We look forward to supporting Abingdon as management continue to diversify and commercialise the Company’s portfolio of exciting rapid tests.”
For more information, visit the Company’s website: https://www.abingdonhealth.com/
For further information please contact:
About Walbrook PR:
Walbrook PR was founded in April 2009 by Paul McManus and focuses on providing high quality Financial PR and Investor Relations to Small Cap and AIM listed companies.
Walbrook PR advises more healthcare companies listed on the London Stock Exchange than any other company and is ranked #2 by number of AIM listed companies with 50 AIM listed clients (Source: AIM Advisers Rankings Guide, October 2021) and ranked #7 by total number of stock market listed clients (Corporate Advisers Rankings Guide, August 2021) advising a total of 58 stock market listed companies across a wide mix of sectors.Walbrook PR prides itself on having a strong reputation for working with growing UK Small Cap and AIM listed companies; a proven IR offering, which focuses on the Private Client Investment Management community and the retail investment community; and on having a proactive, hands-on approach from a committed team with full ownership of the business.